Cart
sales@molnova.com
AT-7519 hydrochloride
CAS No. 902135-91-5
AT-7519 hydrochloride ( AT 7519 Hydrochloride;AT7519 Hydrochloride )
Catalog No. M16486 CAS No. 902135-91-5
A potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 47 | In Stock |
|
| 10MG | 71 | In Stock |
|
| 25MG | 102 | In Stock |
|
| 50MG | 152 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAT-7519 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
-
DescriptionA potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM); has antiproliferative activity against HCT116 cells with IC50 of 82 nM; exhibits good profile against cytochrome P450 isoforms (<30% inhibition at 10 uM for 1A2, 2D6, 3A4, 2C9, 2C19).Blood Cancer Phase 2 Clinical
-
SynonymsAT 7519 Hydrochloride;AT7519 Hydrochloride
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK2/CyclinA;CDK4/CyclinD1;CDK5/p35;CDK9/CyclinT;GSK-3β
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number902135-91-5
-
Formula Weight418.71
-
Molecular FormulaC16H18Cl3N5O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCl.CC1=C(C(=O)NC2=C(NN=C2)C(=O)NC2CCNCC2)C(Cl)=CC=C1
-
Chemical Name1H-Pyrazole-3-carboxamide, 4-[(2,6-dichlorobenzoyl)amino]-N-4-piperidinyl-, hydrochloride (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wyatt PG, et al. J Med Chem. 2008 Aug 28;51(16):4986-99.
2. Squires MS, et al. Mol Cancer Ther. 2009 Feb;8(2):324-32.
3. Dolman ME, et al. Clin Cancer Res. 2015 Nov 15;21(22):5100-9.
2. Squires MS, et al. Mol Cancer Ther. 2009 Feb;8(2):324-32.
3. Dolman ME, et al. Clin Cancer Res. 2015 Nov 15;21(22):5100-9.
molnova catalog
related products
-
CDK4/6-IN-2
CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).
-
Tuberstemonine
Tuberstemonine exhibits relatively higher intestinal permeabilities.
-
SB415286
SB415286 is a potent GSK3α inhibitor with IC50/Ki of 78 nM/31 nM with equally effective inhibition of GSK-3β.
